Why formulation matters for emodepside treatment in dogs

A new pharmacokinetic study is sharpening an important clinical point for veterinarians managing suspected multidrug-resistant canine hookworms: emodepside formulation matters. Investigators reported that the FDA-approved feline topical emodepside/praziquantel solution, when administered orally to dogs, was not bioequivalent to the European canine modified-release emodepside tablet at the same 1 mg/kg dose. Oral use of the feline topical product led to substantially greater systemic absorption, while topical administration produced far lower plasma concentrations than either oral approach. In AVMA’s Veterinary Vertex podcast, the study authors highlighted the size of that difference: compared with the canine tablet, the orally administered feline topical formulation produced an approximately 3-fold higher Cmax and 2.4- to 2.8-fold greater AUC, underscoring that equal mg/kg dosing did not translate into equal rate or extent of absorption. (pubmed.ncbi.nlm.nih.gov)

That finding lands in a clinical space that has been evolving for several years. Multidrug-resistant Ancylostoma caninum has been documented in US dogs, including the Worthy isolate and persistent infections in foxhounds, with resistance reported across the major anthelmintic classes approved for canine hookworm treatment in the US. In that setting, emodepside has attracted attention because studies using the European emodepside/praziquantel dog tablet showed strong efficacy against hookworms, including resistant isolates. Emodepside is also pharmacologically notable because it belongs to the octadepsipeptide class, with a mechanism distinct from the older drug classes now challenged by resistance. (pubmed.ncbi.nlm.nih.gov)

The practical problem is that US veterinarians do not have a canine-labeled emodepside product. Emodepside is FDA-approved in the US as a topical feline product, while in Europe Profender tablets for dogs provide a canine oral formulation. That gap helped drive extra-label interest in using the feline topical product orally in dogs, particularly for refractory hookworm cases. A Clinician’s Brief expert guidance document went so far as to describe emodepside as the only potentially effective alternative if a triple-combination approach fails, while stressing that the drug is not approved for dogs in the US, that precise dosing is critical, and that clinic-administered oral use of the feline product should be approached cautiously. (assets.takeshape.io)

The new AJVR study directly tested whether those formulations behave similarly enough to be treated as interchangeable. In a three-phase crossover study of seven healthy client-owned dogs conducted in 2023, dogs received the feline topical solution orally at 1 mg/kg, the canine modified-release tablet orally at 1 mg/kg, and the feline topical solution topically at 3 mg/kg. The oral feline formulation produced markedly greater absorption than the canine tablet and failed bioequivalence testing. Meanwhile, topical administration of the feline product yielded emodepside plasma concentrations 36- to 122-fold lower than oral administration. The authors concluded that oral use of the feline topical product raises potential safety concerns and that topical dosing may be unsuitable when clinicians are trying to treat multidrug-resistant hookworm infections. (pubmed.ncbi.nlm.nih.gov)

Outside the study itself, the broader literature supports that caution. A 2024 review in Frontiers in Parasitology described emodepside as a promising option against multidrug-resistant infections, but noted key safety concerns, including risk in dogs with MDR1 mutation predisposition and the need for caution in debilitated animals. A published case report also described neurologic adverse reactions after emodepside/praziquantel administration in an MDR1-mutant Australian Shepherd. Those concerns are especially relevant if clinicians had assumed that matching the milligram-per-kilogram dose across formulations would produce comparable exposure. (frontiersin.org)

Why it matters: For veterinarians, this is less a story about one drug than about formulation-dependent pharmacology in off-label medicine. In resistant hookworm cases, there can be understandable pressure to reach for any option with published efficacy. But this study suggests clinicians should not assume that a feline topical product administered orally can stand in for a canine modified-release tablet simply because both contain emodepside. The formulation affects absorption, exposure, and potentially safety. That has implications for informed consent, in-clinic administration, follow-up fecal egg count monitoring, and case selection, particularly in breeds or mixed-breed dogs with possible MDR1 risk. (pubmed.ncbi.nlm.nih.gov)

There’s also a regulatory and market backdrop worth noting. Emodepside originated in veterinary medicine and remains commercially established in animal health, while parallel human development work continues through DNDi and Bayer, including ongoing clinical development for onchocerciasis. That broader interest underscores the molecule’s value, but it does not solve the immediate US companion-animal issue: veterinarians still lack an approved canine formulation domestically, even as resistant hookworm management becomes more complicated. (dndi.org)

What to watch: The next step is likely not a dramatic treatment shift overnight, but more disciplined use of emodepside in refractory cases, closer attention to pharmacokinetic evidence when extrapolating across products, and continued discussion about whether the US market will eventually see canine-specific access or clearer consensus guidance for multidrug-resistant hookworms. (pubmed.ncbi.nlm.nih.gov)